First human GLP-1 gene therapy trial gets green light
Fractyl Health received clinical trial authorization in the Netherlands this week to begin a first-in-human study of RJVA-001in patients with obesity and Type 2 diabetes. “GLP-1 medicines have changed what is possible in obesity and type 2 diabetes, but they require chronic, high-dose systemic exposure that many patients cannot or do not sustain,” Dr. Harith Rajagopalan, CEO of Fractyl Health, said.
- ▪Fractyl Health received clinical trial authorization in the Netherlands this week to begin a first-in-human study of RJVA-001in patients with obesity and Type 2 diabetes.
- ▪“GLP-1 medicines have changed what is possible in obesity and type 2 diabetes, but they require chronic, high-dose systemic exposure that many patients cannot or do not sustain,” Dr.
- ▪Harith Rajagopalan, CEO of Fractyl Health, said.
Opening excerpt (first ~120 words) tap to expand
Healthcare First human GLP-1 gene therapy trial gets green light Comments: by Meg Hilling - 05/16/26 8:41 AM ET Comments: Link copied by Meg Hilling - 05/16/26 8:41 AM ET Comments: Link copied NOW PLAYING (NewsNation) — Health authorities in Europe have given the green light for the first GLP-1 gene therapy trial to take place. Fractyl Health received clinical trial authorization in the Netherlands this week to begin a first-in-human study of RJVA-001in patients with obesity and Type 2 diabetes. “GLP-1 medicines have changed what is possible in obesity and type 2 diabetes, but they require chronic, high-dose systemic exposure that many patients cannot or do not sustain,” Dr. Harith Rajagopalan, CEO of Fractyl Health, said.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Hill.
Discussion
0 commentsMore from The Hill
